文献速递儿童内分泌与遗传代谢

2020至2023年青少年2型糖尿病GLP-1RA配药趋势

GLP-1RA Dispensing in Youth With Type 2 Diabetes: 2020 to 2023.
PubMed 文献 · Pediatrics · 2026-03-02

本研究基于2020至2023年商业与医疗补助保险索赔数据,评估10至17岁2型糖尿病青少年GLP-1RA配药趋势及保险类型差异。GLP-1RA年配药率从2020年10.9%升至2023年35.6%(趋势P<.001),但保险类型间配药率相似,而具体药物类型分布存在差异。

要点

  • 青少年2型糖尿病GLP-1RA配药率从2020年10.9%升至2023年35.6%。
  • 2023年 Medicaid 与商业保险青少年GLP-1RA总配药率相似。
  • Medicaid 青少年司美格鲁肽配药较少,度拉糖肽、艾塞那肽、利拉鲁肽配药较多。

核心结论

  • 青少年2型糖尿病GLP-1RA配药率在2020至2023年间显著上升,但具体药物类型因保险类型而异。

研究设计与样本

  • 多年度横断面研究,使用Merative MarketScan多州Medicaid和商业数据库2020至2023年索赔与就诊数据,纳入10至17岁2型糖尿病青少年。

主要发现

  • GLP-1RA年配药率从2020年10.9%升至2023年35.6%(趋势P<.001)。
  • 2023年GLP-1RA配药率仍低于长效胰岛素(49.5%)和短效胰岛素(43.4%)。
  • 2023年Medicaid与商业保险青少年GLP-1RA总配药率相似。
  • Medicaid保险青少年司美格鲁肽配药率低于商业保险(aPR 0.3,95%CI:0.2-0.4)。
  • Medicaid保险青少年度拉糖肽(aPR 1.5,95%CI:1.2-2.0)、艾塞那肽(aPR 2.3,95%CI:1.2-4.2)、利拉鲁肽(aPR 1.6,95%CI:1.2-2.1)配药率高于商业保险。

关键数值与推荐

  • GLP-1RA年配药率2020年10.9%,2023年35.6%,趋势检验P<.001。
  • 2023年长效胰岛素配药率49.5%,短效胰岛素43.4%。
  • 2023年Medicaid与商业保险比较:司美格鲁肽aPR 0.3(95%CI:0.2-0.4);度拉糖肽aPR 1.5(95%CI:1.2-2.0);艾塞那肽aPR 2.3(95%CI:1.2-4.2);利拉鲁肽aPR 1.6(95%CI:1.2-2.1)。

临床怎么用

  • 儿科医生应了解青少年2型糖尿病中GLP-1RA使用增加的趋势。
  • 处方GLP-1RA时需考虑保险类型对具体药物可及性的潜在影响。

局限性

  • 研究为索赔数据横断面分析,可能受数据库覆盖和处方配药记录准确性限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a novel pharmacotherapeutic option for pediatric type 2 diabetes (T2D); however, little is known about their current use. This study evaluated trends in GLP-1RA dispensing in youth with T2D between 2020 and 2023 and compared use by insurance type (ie, Medicaid vs commercial). METHODS: We conducted a multiyear cross-sectional study of youth aged 10 to 17 years with T2D using Merative™ MarketScan® Multi-State Medicaid and Commercial Database claims and encounters data (2020-2023). Annual prevalence of GLP-1RA dispensing was calculated for each year. Temporal trends in dispensing were examined using the Cochran-Armitage test. Poisson regression with robust variance estimated adjusted prevalence ratios (aPRs) were used to evaluate associations between insurance type (ie, Medicaid vs commercial) and GLP-1RA dispensing in 2023. RESULTS: Annual prevalence of GLP-1RA dispensing in youth with T2D increased from 10.9% in 2020 to 35.6% in 2023 (P value for trend < .001) but remained less frequent than long- (49.5%) and short-acting insulin (43.4%). In 2023, overall GLP-1RA dispensing was similar for Medicaid-insured and commercially insured youth; however, the types of GLP-1RA differed by insurance. Medicaid-insured youth were less likely than commercially insured youth to be dispensed semaglutide (aPR 0.3, 95% CI: 0.2-0.4) and more likely to be dispensed dulaglutide (aPR 1.5, 95% CI: 1.2-2.0), exenatide (aPR 2.3, 95% CI: 1.2-4.2), or liraglutide (aPR 1.6, 95% CI: 1.2-2.1). CONCLUSIONS: GLP-1RA dispensing increased in youth with T2D, but the type of GLP-1RA differed by insurance type. Comparative effectiveness studies and research identifying barriers to GLP-1RA use are needed to ensure optimal treatment of youth with T2D.

来源:Pediatrics,查看原文。版权归原作者所有。

引用

  1. Chu PY, Kelly A, Hennessy S, et al. GLP-1RA Dispensing in Youth With Type 2 Diabetes: 2020 to 2023. Pediatrics. 2026. PMID: 41765350. doi:10.1542/peds.2025-071971

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。